查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2087931

口服疫苗市場：按疫苗類型、疾病、年齡層和分銷管道分類的全球市場預測，2026-2032年

Oral Vaccine Market by Vaccine Type, Disease Indication, Age Group, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，口服疫苗市場規模將達到 73.4 億美元，複合年成長率為 8.43%。

主要市場統計數據
基準年 2025 41.6億美元
預計年份：2026年 44.8億美元
預測年份 2032 73.4億美元
複合年成長率 (%) 8.43%

將口服疫苗推向市場

口服疫苗市場處於感染疾病控制、黏膜免疫學、集體爆發防治和大規模免疫接種的交會點。口服疫苗備受青睞，因為它們能夠刺激黏膜表面產生免疫反應，比注射疫苗更容易接種，即使在訓練有素的負責人、無菌注射材料和診所接種能力有限的環境中，也能支持大規模免疫宣傳活動。

口服疫苗領域的變革性變化

口服疫苗的格局正從產品供應轉向專案韌性、公平取得和對集體爆發的快速反應。全球口服脊髓灰質炎疫苗的經驗表明，大規模、便捷的接種方式至關重要，同時也表明，高疫苗接種率、監測和謹慎的毒株選擇對於降低低疫苗接種率社區中疫苗衍生脊髓灰質炎的風險至關重要。

人工智慧（AI）的累積影響

人工智慧 (AI) 正日益成為口服疫苗發現、開發、生產和上市後監測等整體的有力驅動力。在研究領域，AI 驅動的建模可以支持抗原優先排序、免疫表位預測、病毒株演化評估以及製劑穩定性和黏膜給藥性能的篩檢。當這些應用與檢驗的實驗室檢測、臨床證據和符合監管標準的品管系統相結合時，才能發揮最大價值。

關於口服疫苗的關鍵區域性見解

亞太地區是口服疫苗的主要成長市場，這得益於其龐大的出生人口、高人口密度以及對常規免疫接種的持續投入。印度和中國憑藉其國內生產規模、國家免疫接種優先事項以及不斷提升的生物技術能力，正在影響全球供需關係。同時，東南亞市場受益於捐助者支持的疫苗接種、區域疾病監測以及對預防輪狀病毒、霍亂、傷寒和脊髓灰質炎的持續關注。

主要經濟領域的關鍵群體洞察

在東協市場，隨著免疫系統的加強、地方監管機構之間的合作以及對霍亂、傷寒和兒童腹瀉預防的日益重視，口服疫苗的使用正在不斷擴大。在海灣合作理事會國家，高所得水準的醫療保健體系，加上與旅行、移民和朝聖相關的健康安全需求，推動了對有針對性的口服疫苗儲備、旅行者保護和緊急應變協調的需求。

主要口服疫苗市場的國家/地區特定洞察

美國和加拿大優先考慮嚴格的監管審查、旅行者疫苗接種、臨床創新、免疫安全監測以及應對感染疾病疫情的準備工作，而墨西哥和巴西則透過公共免疫計劃、兒童疫苗的引入和疾病監測來支持區域需求。在歐洲，英國、德國、法國、義大利和西班牙透過歐洲體系提供先進的研究能力、採購系統、臨床試驗基礎設施和監管協調，而俄羅斯則維持其國內疫苗生產能力和戰略性免疫計畫。

為行業領導者提供的實用建議

產業領導者應優先考慮建立具有韌性的供應鏈、多樣化的抗原和製劑研發管線，以及能夠滿足常規免疫接種需求和應對突發疫情需求激增的生產夥伴關係。投資於耐熱口服疫苗技術、提高包裝效率、加強株監測和降低生產成本，可以改善那些低溫運輸限制和免疫宣傳活動物流仍然是障礙的市場的疫苗可及性。

調查方法

本執行摘要系統性地彙編自經過核實的公共衛生、監管和市場相關資訊來源，包括世界衛生組織指南、聯合國兒童基金會和全球疫苗免疫聯盟的採購情況、國家免疫規劃實踐、監管框架、同行評審證據以及既定的疫苗安全原則。本分析著重於事實徵兆，而非檢驗的市場聲明、規模假設或基於預測的結論。

結論

口服疫苗因其兼具公共衛生有效性和操作便利性，仍是全球免疫接種的重要組成部分。其價值在預防兒童疾病、大規模免疫宣傳活動、應對感染疾病疫情、旅遊醫學以及難以進行大規模注射接種等情況下尤為顯著。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 口服疫苗市場：依疫苗類型分類

  • 結合疫苗
  • 去活化疫苗
    • 全細胞失活
    • 類毒素鹼
  • 減毒活疫苗
    • 細菌
    • 病毒性的
  • 藥效疫苗
  • 次單位疫苗
    • 蛋白質次單元
    • 多醣體次單元

第8章 口服疫苗市場：依疾病適應症分類

  • 流感
  • 諾羅病毒
  • 脊髓灰質炎
  • 輪狀病毒

第9章 口服疫苗市場：依年齡層別分類

  • 成人
  • 老年人
  • 兒童

第10章 口服疫苗市場：依通路分類

  • 線上
  • 離線

第11章 口服疫苗市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章 口服疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 口服疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • AstraZeneca plc
  • Bharat Biotech International Limited
  • Biological E. Limited
  • Cadila Healthcare Limited
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc
  • Indian Immunologicals Limited
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novavax, Inc.
  • Oramed Pharmaceuticals Inc.
  • Panacea Biotec Limited
  • Pfizer Inc.
  • Sanofi SA
  • Serum Institute of India Private Limited
  • Valneva SE
  • Vaxart, Inc.
Product Code: MRR-035DA3C63714

The Oral Vaccine Market is projected to grow by USD 7.34 billion at a CAGR of 8.43% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.16 billion
Estimated Year [2026] USD 4.48 billion
Forecast Year [2032] USD 7.34 billion
CAGR (%) 8.43%

Oral Vaccine Market Executive Introduction

The oral vaccine market sits at the intersection of infectious disease control, mucosal immunology, outbreak preparedness, and scalable immunization delivery. Oral vaccines are valued because they can stimulate immune responses at mucosal surfaces, simplify administration compared with injectable products, and support mass vaccination campaigns in settings where trained vaccinators, sterile injection supplies, and clinic-based delivery capacity are constrained.

Commercial and public health demand is anchored by established products such as oral polio vaccine, rotavirus vaccines, oral cholera vaccines, and oral typhoid vaccines. The category is also gaining strategic attention as governments, multilateral buyers, and manufacturers pursue thermostable formulations, improved supply security, and next-generation platforms that can reduce logistical friction across routine immunization, travel medicine, and emergency response.

Transformative Shifts in the Oral Vaccine Landscape

The oral vaccine landscape is shifting from product availability toward program resilience, equity of access, and rapid outbreak response. Global experience with oral polio vaccine demonstrates the value of easy administration at scale, while also showing the importance of high coverage, surveillance, and careful strain selection to reduce vaccine-derived poliovirus risk in under-immunized communities.

Rotavirus and cholera vaccination programs are accelerating the focus on affordability, cold-chain optimization, and supply diversification. The global cholera resurgence reported by the World Health Organization has intensified demand for oral cholera vaccine stockpiles, while rotavirus vaccine adoption in national immunization schedules continues to support pediatric disease prevention in low- and middle-income countries.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a practical accelerator across oral vaccine discovery, development, manufacturing, and post-market monitoring. In research, AI-enabled modeling can help prioritize antigens, predict immune epitopes, assess strain evolution, and support formulation screening for stability and mucosal delivery performance. These applications are most valuable when paired with validated laboratory assays, clinical evidence, and regulatory-grade quality systems.

AI also strengthens demand forecasting, pharmacovigilance signal detection, cold-chain planning, and outbreak allocation decisions. For oral vaccines used in emergency campaigns, such as oral cholera vaccine and oral polio vaccine, predictive analytics can help public health agencies align stockpiles, distribution timing, and population targeting with epidemiological risk while maintaining human oversight and transparent governance.

Key Regional Insights for Oral Vaccines

Asia-Pacific is a major growth arena for oral vaccines because of large birth cohorts, high population density, and continued investment in routine immunization. India and China influence global supply and demand through domestic manufacturing scale, national immunization priorities, and expanding biotechnology capabilities, while Southeast Asian markets benefit from donor-supported vaccination, regional disease surveillance, and continued focus on rotavirus, cholera, typhoid, and polio prevention.

North America and Europe are characterized by mature regulatory systems, travel vaccine demand, advanced pharmacovigilance, and strong clinical development infrastructure. In North America, oral vaccine demand is shaped by traveler protection, outbreak readiness, and evidence-based immunization guidance, while Europe supports clinical quality standards, centralized regulatory coordination, and public-sector procurement discipline. Latin America remains important for rotavirus vaccine uptake, outbreak preparedness, and public-sector procurement, supported by regional experience in immunization campaigns and diarrheal disease control. The Middle East increasingly links immunization planning with humanitarian response, migration, pilgrimage health security, and regional cold-chain modernization. Africa represents one of the most consequential demand centers for oral polio vaccine, rotavirus vaccines, and oral cholera vaccines due to disease burden, emergency campaigns, cross-border transmission risks, and the strategic role of WHO-, UNICEF-, and Gavi-supported programs.

Key Group Insights Across Major Economic Blocs

ASEAN markets are advancing oral vaccine access through immunization strengthening, local regulatory cooperation, and growing attention to cholera, typhoid, and pediatric diarrheal disease prevention. The GCC combines high-income health systems with travel, migration, and pilgrimage-related health security needs, supporting demand for targeted oral vaccine preparedness, traveler protection, and emergency response coordination.

The European Union and G7 shape standards for clinical evidence, vaccine safety monitoring, financing, procurement quality, and manufacturing oversight, reinforcing the role of transparent regulatory pathways and post-market surveillance in oral vaccine adoption. NATO countries increasingly view vaccine supply security, stockpile planning, and resilient logistics as part of broader health security and civil preparedness. BRICS nations are especially influential because China, India, Brazil, Russia, and South Africa combine large populations, public procurement power, expanding vaccine manufacturing capacity, and technology-transfer priorities that can affect global oral vaccine availability and access.

Key Country Insights in Leading Oral Vaccine Markets

The United States and Canada emphasize stringent regulatory review, traveler vaccination, clinical innovation, immunization safety monitoring, and outbreak readiness, while Mexico and Brazil support regional demand through public immunization programs, pediatric vaccine adoption, and disease surveillance. In Europe, the United Kingdom, Germany, France, Italy, and Spain contribute advanced research capacity, procurement discipline, clinical trial infrastructure, and regulatory alignment through European systems, while Russia maintains domestic vaccine production capabilities and strategic immunization programs.

China and India are central to oral vaccine manufacturing, scale-up economics, and national disease control priorities, with both countries playing influential roles in pediatric immunization, outbreak response, and supply continuity. Japan, Australia, and South Korea add high-quality clinical research, advanced cold-chain infrastructure, strong regulatory oversight, and regional health security leadership, strengthening Asia-Pacific's role in next-generation oral vaccine development and deployment.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize resilient supply chains, diversified antigen and formulation pipelines, and manufacturing partnerships that can respond to both routine immunization demand and emergency outbreak surges. Investments in thermostable oral vaccine technologies, packaging efficiency, strain surveillance, and lower-cost production can improve access in markets where cold-chain limitations and campaign logistics remain persistent barriers.

Organizations should also strengthen evidence generation for mucosal immunity, duration of protection, safety in target age groups, co-administration with routine vaccines, and real-world effectiveness. Strategic alignment with WHO prequalification pathways, national immunization technical advisory groups, donor procurement requirements, regulatory quality expectations, and digital pharmacovigilance systems will be essential for credible market entry and sustainable adoption.

Research Methodology

This executive summary is developed through a structured synthesis of verified public health, regulatory, and market-relevant sources, including WHO guidance, UNICEF and Gavi procurement context, national immunization program practices, regulatory agency frameworks, peer-reviewed evidence, and established vaccine safety principles. The analysis emphasizes factual signals rather than speculative market claims, sizing assumptions, or forecast-based conclusions.

The methodology evaluates product categories, disease burden drivers, regional immunization dynamics, procurement mechanisms, regulatory pathways, technology trends, and supply-chain constraints. Insights are cross-checked for consistency across public health priorities, commercial feasibility, and operational realities affecting oral polio, rotavirus, cholera, and typhoid vaccine deployment.

Conclusion

Oral vaccines remain a critical segment of global immunization because they combine public health impact with operational simplicity. Their value is most visible in pediatric disease prevention, mass campaigns, outbreak response, travel medicine, and settings where injectable delivery is harder to sustain at scale.

The future of the oral vaccine market will be shaped by supply reliability, next-generation mucosal delivery science, AI-supported development, and policy alignment across countries and procurement bodies. Organizations that invest in evidence, affordability, manufacturing resilience, quality systems, and equitable access will be best positioned to support this evolving market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Oral Vaccine Market, by Vaccine Type

  • 7.1. Conjugate Vaccines
  • 7.2. Inactivated Vaccines
    • 7.2.1. Whole-Cell Inactivated
    • 7.2.2. Toxoid-Based
  • 7.3. Live Attenuated Vaccines
    • 7.3.1. Bacterial
    • 7.3.2. Viral
  • 7.4. Mrna Vaccines
  • 7.5. Subunit Vaccines
    • 7.5.1. Protein Subunit
    • 7.5.2. Polysaccharide Subunit

8. Oral Vaccine Market, by Disease Indication

  • 8.1. Influenza
  • 8.2. Norovirus
  • 8.3. Poliovirus
  • 8.4. Rotavirus

9. Oral Vaccine Market, by Age Group

  • 9.1. Adult
  • 9.2. Geriatric
  • 9.3. Pediatric

10. Oral Vaccine Market, by Distribution Channel

  • 10.1. Online
  • 10.2. Offline

11. Oral Vaccine Market, by Region

  • 11.1. Asia-Pacific
  • 11.2. North America
  • 11.3. Latin America
  • 11.4. Europe
  • 11.5. Middle East
  • 11.6. Africa

12. Oral Vaccine Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Oral Vaccine Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Concentration Analysis, 2025
    • 14.1.1. Concentration Ratio (CR)
    • 14.1.2. Herfindahl Hirschman Index (HHI)
  • 14.2. Recent Developments & Impact Analysis, 2025
  • 14.3. Product Portfolio Analysis, 2025
  • 14.4. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. AstraZeneca plc
  • 15.2. Bharat Biotech International Limited
  • 15.3. Biological E. Limited
  • 15.4. Cadila Healthcare Limited
  • 15.5. Emergent BioSolutions Inc.
  • 15.6. GlaxoSmithKline plc
  • 15.7. Indian Immunologicals Limited
  • 15.8. Johnson & Johnson
  • 15.9. Merck & Co., Inc.
  • 15.10. Novavax, Inc.
  • 15.11. Oramed Pharmaceuticals Inc.
  • 15.12. Panacea Biotec Limited
  • 15.13. Pfizer Inc.
  • 15.14. Sanofi S.A.
  • 15.15. Serum Institute of India Private Limited
  • 15.16. Valneva SE
  • 15.17. Vaxart, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ORAL VACCINE MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ORAL VACCINE MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ORAL VACCINE MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ORAL VACCINE MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ORAL VACCINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL ORAL VACCINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ORAL VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ORAL VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ORAL VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ORAL VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ORAL VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ORAL VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CONJUGATE VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CONJUGATE VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONJUGATE VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INACTIVATED VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INACTIVATED VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INACTIVATED VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL WHOLE-CELL INACTIVATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL WHOLE-CELL INACTIVATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL WHOLE-CELL INACTIVATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TOXOID-BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TOXOID-BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TOXOID-BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LIVE ATTENUATED VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LIVE ATTENUATED VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LIVE ATTENUATED VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BACTERIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BACTERIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BACTERIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL VIRAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL VIRAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL VIRAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MRNA VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MRNA VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MRNA VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SUBUNIT VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SUBUNIT VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SUBUNIT VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PROTEIN SUBUNIT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PROTEIN SUBUNIT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PROTEIN SUBUNIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL POLYSACCHARIDE SUBUNIT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL POLYSACCHARIDE SUBUNIT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL POLYSACCHARIDE SUBUNIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INFLUENZA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INFLUENZA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INFLUENZA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NOROVIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NOROVIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NOROVIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL POLIOVIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL POLIOVIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL POLIOVIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ROTAVIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ROTAVIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ROTAVIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PEDIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PEDIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PEDIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ORAL VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ORAL VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. GCC ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 125. GCC ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. GCC ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 127. GCC ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 128. GCC ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2018-2032 (USD MILLION)
  • TABLE 129. GCC ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 130. GCC ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GCC ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. G7 ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 149. G7 ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. G7 ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 151. G7 ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 152. G7 ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2018-2032 (USD MILLION)
  • TABLE 153. G7 ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. G7 ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. G7 ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. NATO ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 157. NATO ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. NATO ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 159. NATO ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 160. NATO ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2018-2032 (USD MILLION)
  • TABLE 161. NATO ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 162. NATO ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 163. NATO ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. CANADA ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. CANADA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. CANADA ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 176. CANADA ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 177. CANADA ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2018-2032 (USD MILLION)
  • TABLE 178. CANADA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 179. CANADA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. CANADA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. MEXICO ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. MEXICO ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. MEXICO ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 184. MEXICO ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 185. MEXICO ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2018-2032 (USD MILLION)
  • TABLE 186. MEXICO ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 187. MEXICO ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. MEXICO ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. BRAZIL ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. BRAZIL ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. BRAZIL ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 192. BRAZIL ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 193. BRAZIL ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2018-2032 (USD MILLION)
  • TABLE 194. BRAZIL ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. BRAZIL ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. BRAZIL ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED KINGDOM ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED KINGDOM ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. GERMANY ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. GERMANY ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. GERMANY ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 208. GERMANY ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 209. GERMANY ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2018-2032 (USD MILLION)
  • TABLE 210. GERMANY ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 211. GERMANY ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. GERMANY ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 213. FRANCE ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 214. FRANCE ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. FRANCE ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 216. FRANCE ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 217. FRANCE ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2018-2032 (USD MILLION)
  • TABLE 218. FRANCE ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 219. FRANCE ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 220. FRANCE ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. RUSSIA ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 222. RUSSIA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. RUSSIA ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 224. RUSSIA ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 225. RUSSIA ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2018-2032 (USD MILLION)
  • TABLE 226. RUSSIA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 227. RUSSIA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. RUSSIA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 229. ITALY ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. ITALY ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. ITALY ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 232. ITALY ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 233. ITALY ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2018-2032 (USD MILLION)
  • TABLE 234. ITALY ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 235. ITALY ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 236. ITALY ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. SPAIN ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 238. SPAIN ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. SPAIN ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 240. SPAIN ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 241. SPAIN ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2018-2032 (USD MILLION)
  • TABLE 242. SPAIN ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 243. SPAIN ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 244. SPAIN ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. INDIA ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. INDIA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. INDIA ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 256. INDIA ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 257. INDIA ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2018-2032 (USD MILLION)
  • TABLE 258. INDIA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 259. INDIA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 260. INDIA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. JAPAN ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. JAPAN ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. JAPAN ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 264. JAPAN ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 265. JAPAN ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2018-2032 (USD MILLION)
  • TABLE 266. JAPAN ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 267. JAPAN ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 268. JAPAN ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 269. AUSTRALIA ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 270. AUSTRALIA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. AUSTRALIA ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 272. AUSTRALIA ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 273. AUSTRALIA ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2018-2032 (USD MILLION)
  • TABLE 274. AUSTRALIA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 275. AUSTRALIA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 276. AUSTRALIA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 277. SOUTH KOREA ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. SOUTH KOREA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. SOUTH KOREA ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 280. SOUTH KOREA ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, 2018-2032 (USD MILLION)
  • TABLE 281. SOUTH KOREA ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, 2018-2032 (USD MILLION)
  • TABLE 282. SOUTH KOREA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 283. SOUTH KOREA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 284. SOUTH KOREA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)